Enhancement of T-cell-mediated antitumor response: angiostatic adjuvant to immunotherapy against cancer.
about
Trial Watch: Adoptive cell transfer for oncological indicationsGenetically modified T cells for the treatment of malignant diseaseRapid angiogenesis onset after discontinuation of sunitinib treatment of renal cell carcinoma patientsModifying Dendritic Cell Activation with Plasmonic Nano VectorsAntitumor agent calixarene 0118 targets human galectin-1 as an allosteric inhibitor of carbohydrate bindingTrial Watch: Adoptive cell transfer immunotherapy.Structure-based optimization of angiostatic agent 6DBF7, an allosteric antagonist of galectin-1.Trial Watch: Adoptive cell transfer for anticancer immunotherapy.Targeted vaccination against the bevacizumab binding site on VEGF using 3D-structured peptides elicits efficient antitumor activity.The Role of the Tumor Vasculature in the Host Immune Response: Implications for Therapeutic Strategies Targeting the Tumor Microenvironment.Adoptive T cell therapy promotes the emergence of genomically altered tumor escape variants.Antiangiogenic therapy improves the antitumor effect of adoptive cell immunotherapy by normalizing tumor vasculature.The emerging quest for the optimal angiostatic combination therapy.Functionalized calix[4]arenes as potential therapeutic agents.Anti-angiogenesis for cancer revisited: Is there a role for combinations with immunotherapy?Local expression of interleukin-2 by B16 melanoma cells results in decreased tumour growth and long-term tumour dormancy.Resistance to Antiangiogenic Therapy Is Associated with an Immunosuppressive Tumor Microenvironment in Metastatic Renal Cell Carcinoma.Reply to Marchiò et al.: Antitumor immune regulation by angiostatic therapy.Trial Watch: Adoptive cell transfer for anticancer immunotherapy.Galectin-1 Inhibitor OTX008 Induces Tumor Vessel Normalization and Tumor Growth Inhibition in Human Head and Neck Squamous Cell Carcinoma Models.Triple-negative breast cancer targeting and killing by EpCAM-directed, plasmonically active nanodrug systems.Galectins as Molecular Targets for Therapeutic Intervention.
P2860
Q26785545-A3D3BF6B-C871-4E64-9C79-B4538E34AF94Q26860657-81D34EBA-5398-416E-A827-FF37C156C64EQ33588739-BCC17671-3554-40A0-8413-CBF3705D6647Q33906222-64C2A8F6-4691-4BC7-B4B3-FA36010C0BEDQ34564173-31FCD850-CB5D-4213-862A-E199B058668BQ36057432-3F423F9B-3CF2-4AC8-9041-E2494DF41BE6Q36642433-78F7996A-0F31-4362-87D5-EE74C27C610BQ36887833-8BD60BEF-9AC4-4FB9-9B5E-B2C12BA7CFCEQ37398065-F6DA5885-ACFA-42A4-99EA-0748A07720A6Q37516448-297FFBF8-0516-4D5D-81F5-079F0F54440EQ37519025-DB56913E-17B4-4F2B-8608-5E46E3FF801AQ38132055-06CFF549-BC43-4199-8D43-61932E4CEF82Q38268453-2EC9AB16-B527-483F-A32D-9A54B3CE5287Q39138272-BC6D7C15-8419-4719-9561-0DBAA20375DEQ39210287-994F8EB5-6B5B-4BFA-B893-CBB2A85DC9CDQ39235364-086AC16C-ABA8-454A-91BB-8EEEC40C5BFBQ41789122-47034085-EA01-4B3A-B5BA-9A50CE025815Q42290718-D08BE4D9-F6A6-4113-949F-3430D50C0A92Q42702234-7028EA6E-C44E-42DE-8C13-5D710D63FAA8Q47302234-A959149E-AFEA-4A2E-8B65-76AF3BA7371CQ54995893-620A7E58-2979-42D1-BA55-0C60E5A0A2E8Q55316400-FDAB3430-9EDC-4D59-A7D2-37F0AC6C1F68
P2860
Enhancement of T-cell-mediated antitumor response: angiostatic adjuvant to immunotherapy against cancer.
description
2011 nî lūn-bûn
@nan
2011 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Enhancement of T-cell-mediated ...... immunotherapy against cancer.
@ast
Enhancement of T-cell-mediated ...... immunotherapy against cancer.
@en
Enhancement of T-cell-mediated ...... immunotherapy against cancer.
@nl
type
label
Enhancement of T-cell-mediated ...... immunotherapy against cancer.
@ast
Enhancement of T-cell-mediated ...... immunotherapy against cancer.
@en
Enhancement of T-cell-mediated ...... immunotherapy against cancer.
@nl
prefLabel
Enhancement of T-cell-mediated ...... immunotherapy against cancer.
@ast
Enhancement of T-cell-mediated ...... immunotherapy against cancer.
@en
Enhancement of T-cell-mediated ...... immunotherapy against cancer.
@nl
P2093
P2860
P1476
Enhancement of T-cell-mediated ...... immunotherapy against cancer.
@en
P2093
Arjan W Griffioen
Flavia Popescu
Karolien Castermans
Kevin H Mayo
Kieng B Vang
Matthew F Mescher
Michael A Farrar
Mirjam G A Oude Egbrink
Ruud P M Dings
P2860
P304
P356
10.1158/1078-0432.CCR-10-2443
P407
P577
2011-01-20T00:00:00Z